Australia is closely awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://georgiabtwp568685.jasperwiki.com/7915985/this_new_drug_retatrutide_australia_a_potential_hope_for_obesity_treatment